FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385655227> ?p ?o ?g. }

• W4385655227 endingPage "e44729a5" @default.
• W4385655227 startingPage "e44729a5" @default.
• W4385655227 abstract "Topic: 19. Aggressive Non-Hodgkin lymphoma - Clinical Background: Consolidation therapy improves duration of response in primary central nerves system lymphoma (PCNSL). Lenalidomide maintenance has shown potential activity in elder adults with PCNSL. However,the efficacy of front-line lenalidomide maintenance in non-elder PCNSL has never been elevated. Aims: We aim to evaluate the effect of lenalidomide maintenance on duration of response in newly-diagnosed PCNSLs Methods: This is a retrospective, single-center analysis. The patients with PCNSL who achieved complete remission or partial remission after high-dose methotrexate induction therapy were enrolled. Lenalidomide maintenance of 25 mg/d was administered orally for 21 days of every 28-day for 24 months in 35 patients, and no further treatment in the observe group. The efficacy and safety data were analysis. Results: 69 patients were enrolled at Peking Union Medical College Hospital from 2003 to 2021. The median age was 58.0 years, and 50.7% (n=35) were male. Patients totaling to 57 (82.6%) achieved CR and 12 (18.4%) achieved PR status. Thirty-five patients received lenalidomide maintenance, the median duration of lenalidomide was 18 (2-36) months. it was well tolerated and barely affected the quality of life. After a median follow-up of 32.6 months, there were less relapsing and death events in the maintenance group. However, the median PFS was similar between groups (36.1months vs 30.6months, HR 0.78, p 0.446), so did median OS (HR 0.4263, p 0.091). In the PR patients after induction, lenalidomide maintenance improved PFS and OS significantly. Summary/Conclusion: This is the first study to compare lenalidomide maintenance with observe as frontline treatment in PCNSL, the improvement of PFS and OS were not observed, although the safety profile was satisfied. Funding: CAMS Innovation Fund for Medical Sciences（CIFMS）2021-I2M-C&T-B-005. Correspondence to: Daobin Zhou, MD Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College No.1 Shuaifuyuan Wangfujing Dongcheng District Beijing, China, 100730 Keywords: Lymphoma therapy, Lymphoma, Non-Hodgkin’s lymphoma" @default.
• W4385655227 created "2023-08-09" @default.
• W4385655227 creator A5003339044 @default.
• W4385655227 creator A5006052857 @default.
• W4385655227 creator A5045814990 @default.
• W4385655227 creator A5056248574 @default.
• W4385655227 creator A5061265927 @default.
• W4385655227 creator A5072101455 @default.
• W4385655227 creator A5072330498 @default.
• W4385655227 creator A5086664284 @default.
• W4385655227 date "2023-08-01" @default.
• W4385655227 modified "2023-10-14" @default.
• W4385655227 title "PB2347: THE ROLE OF UPFRONT LENALIDOMIDE MAINTENANCE FOR PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA PATIENTS RESPONDING TO FIRST-LINE MTX TREATMENT" @default.
• W4385655227 doi "https://doi.org/10.1097/01.hs9.0000976108.44729.a5" @default.
• W4385655227 hasPublicationYear "2023" @default.
• W4385655227 type Work @default.
• W4385655227 citedByCount "0" @default.
• W4385655227 crossrefType "journal-article" @default.
• W4385655227 hasAuthorship W4385655227A5003339044 @default.
• W4385655227 hasAuthorship W4385655227A5006052857 @default.
• W4385655227 hasAuthorship W4385655227A5045814990 @default.
• W4385655227 hasAuthorship W4385655227A5056248574 @default.
• W4385655227 hasAuthorship W4385655227A5061265927 @default.
• W4385655227 hasAuthorship W4385655227A5072101455 @default.
• W4385655227 hasAuthorship W4385655227A5072330498 @default.
• W4385655227 hasAuthorship W4385655227A5086664284 @default.
• W4385655227 hasBestOaLocation W43856552271 @default.
• W4385655227 hasConcept C126322002 @default.
• W4385655227 hasConcept C141071460 @default.
• W4385655227 hasConcept C143998085 @default.
• W4385655227 hasConcept C2776063141 @default.
• W4385655227 hasConcept C2776364478 @default.
• W4385655227 hasConcept C2776694085 @default.
• W4385655227 hasConcept C2778283404 @default.
• W4385655227 hasConcept C2781059491 @default.
• W4385655227 hasConcept C2781173314 @default.
• W4385655227 hasConcept C71924100 @default.
• W4385655227 hasConceptScore W4385655227C126322002 @default.
• W4385655227 hasConceptScore W4385655227C141071460 @default.
• W4385655227 hasConceptScore W4385655227C143998085 @default.
• W4385655227 hasConceptScore W4385655227C2776063141 @default.
• W4385655227 hasConceptScore W4385655227C2776364478 @default.
• W4385655227 hasConceptScore W4385655227C2776694085 @default.
• W4385655227 hasConceptScore W4385655227C2778283404 @default.
• W4385655227 hasConceptScore W4385655227C2781059491 @default.
• W4385655227 hasConceptScore W4385655227C2781173314 @default.
• W4385655227 hasConceptScore W4385655227C71924100 @default.
• W4385655227 hasIssue "S3" @default.
• W4385655227 hasLocation W43856552271 @default.
• W4385655227 hasLocation W43856552272 @default.
• W4385655227 hasOpenAccess W4385655227 @default.
• W4385655227 hasPrimaryLocation W43856552271 @default.
• W4385655227 hasRelatedWork W2000304045 @default.
• W4385655227 hasRelatedWork W2033089666 @default.
• W4385655227 hasRelatedWork W2150885028 @default.
• W4385655227 hasRelatedWork W2230048083 @default.
• W4385655227 hasRelatedWork W2496924072 @default.
• W4385655227 hasRelatedWork W2547590150 @default.
• W4385655227 hasRelatedWork W2791182448 @default.
• W4385655227 hasRelatedWork W2801448674 @default.
• W4385655227 hasRelatedWork W2981037580 @default.
• W4385655227 hasRelatedWork W4312064867 @default.
• W4385655227 hasVolume "7" @default.
• W4385655227 isParatext "false" @default.
• W4385655227 isRetracted "false" @default.
• W4385655227 workType "article" @default.